Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.65 |
| ▸ | PGR | P06401 | 6/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.65 |
| ▸ | TNF | P01375 | 1/20 | 0.65 |
| ▸ | IL6 | P05231 | 1/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.65 |
| ▸ | AR | P10275 | 1/20 | 0.65 |
| ▸ | GLUL | P15104 | 1/20 | 0.65 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.65 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL22042712 | 0.92 | NR3C1 (0.67) | HIF1ALMNANR3C1NR3C2PGR | |
| SCHEMBL945986 | 0.92 | NR3C1 (0.67) | HIF1ALMNANR3C1NR3C2PGR | |
| SCHEMBL11016342 | 0.91 | NR3C2 (0.72) | HIF1ALMNANR3C1NR3C2PGR | |
| SCHEMBL6857093 | 0.91 | NR3C2 (0.72) | HIF1ALMNANR3C1NR3C2PGR | |
| SCHEMBL6857090 | 0.91 | NR3C2 (0.72) | HIF1ALMNANR3C1NR3C2PGR | |
| Prednival SCHEMBL25388 | 0.90 | HIF1A (0.73) | HIF1ALMNANR3C1NR3C2PGR | |
| SCHEMBL1945625 | 0.90 | NR3C1 (0.67) | HIF1ALMNANR3C1NR3C2PGR | |
| SCHEMBL1945621 | 0.90 | NR3C1 (0.67) | HIF1ALMNANR3C1NR3C2PGR | |
| Prednival SCHEMBL2966209 | 0.90 | HIF1A (0.73) | HIF1ALMNANR3C1NR3C2PGR | |
| Prednival SCHEMBL25387 | 0.90 | HIF1A (0.73) | HIF1ALMNANR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113660952-B | Bispecific antibodies | 小野药品工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-111670203-B | bispecific antibodies | 小野药品工业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| US-20230041980-A1 | METHOD OF PROTECTING A RESPIRATORY TRACT OR A LUNG FROM DAMAGE, METHOD OF PROTECTING A LUNG FROM PRESSURE DAMAGE INDUCED BY A VENTILATOR, METHOD OF SUPPRESSING SPREAD OF INFECTION WITH VIRUSES OR BACTERIA THAT CAUSE PNEUMONIA IN PULMONARY BRONCHIAL EPITHELIAL CELLS OR ALVEOLAR EPITHELIAL CELLS, AND NASAL SPRAY | NEXT21 KABUSHIKI KAISHA (JP) | 2023-02-09 | — | — | US | disclosed |
| EP-4125927-A1 | MEDICINE CONTAINING TREHALOSE OR TREHALOSE DERIVATIVE AND NASAL SPRAY | Next21 Kabushiki Kaisha (JP) | 2023-02-08 | — | — | EP | disclosed |
| US-20220142915-A1 | Dental Local Anesthetic Solution | SHOWAKAI MEDICAL CO. (JP) | 2022-05-12 | — | — | US | disclosed |
| EP-3995132-A1 | DENTAL LOCAL ANESTHETIC SOLUTION | Showakai Medical Co. (JP) | 2022-05-11 | — | — | EP | disclosed |
| WO-2021210648-A1 | MEDICINE CONTAINING TREHALOSE OR TREHALOSE DERIVATIVE AND NASAL SPRAY | NEXT21 KABUSHIKI KAISHA (JP) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021025140-A1 | DUAL-SPECIFIC PROTEIN | 小野薬品工業株式会社 | 2021-02-11 | — | — | WO | disclosed |
| WO-2021020416-A1 | BISPECIFIC ANTIBODY | 小野薬品工業株式会社 | 2021-02-04 | — | — | WO | disclosed |
| WO-2019177117-A1 | DRUG FOR TREATING COUGH | 日本ケミファ株式会社 | 2019-09-19 | — | — | WO | disclosed |
| EP-1550461-A1 | REMEDY FOR CHRONIC DISEASE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-06 | — | — | EP | disclosed |
| US-20050020634-A1 | Coumarin derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1495756-A1 | SEVERE SEPSIS PREVENTIVE THERAPEUTIC AGENT | Takeda Chemical Industries, Ltd. (JP) | 2005-01-12 | — | — | EP | disclosed |
| EP-1471064-A1 | COUMARIN DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-20030232809-A1 | Lipid-rich plaque inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1302470-A1 | LIPID-RICH PLAQUE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-04-16 | — | — | EP | disclosed |
| EP-1197209-A1 | PERCUTANEOUSLY ABSORBABLE PREPARATIONS | HISAMITSU PHARMACEUTICAL CO. INC. (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-0953357-A1 | NEPHROTROPIC DRUGS | Drug Delivery System Institute, Ltd. (JP) | 1999-11-03 | — | — | EP | disclosed |
| EP-0215313-A2 | Emulsion compositions for the parenteral and/or oral administration of sparingly water soluble ionizable hydrophobic drugs | AMERICAN CYANAMID COMPANY (US) | 1987-03-25 | — | — | EP | disclosed |
| US-4440764-A | ANTISHOCK, ANTIALLERGEN IMMUNOSUPPRESSIVE AND INTRA-ARTICULAR THERAPY | GRUPPO LEPETIT S.P.A. (IT) | 1984-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020634-A1 | Coumarin derivatives, process for their production and use thereof | CBR1, ACAT2, CBR3 | NR3C1 3476/4885HIF1A 560/4885LMNA 1063/4885 |
| US-20030232809-A1 | Lipid-rich plaque inhibitors | LDLR, NR1H2, NR1H3 | NR3C1 43/4885HIF1A 622/4885LMNA 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.